Author/Authors :
Masayuki Matsushita، نويسنده , , Timothy Z. Hoffman، نويسنده , , Jon A. Ashley، نويسنده , , Bin Zhou، نويسنده , , Peter Wirsching، نويسنده , , Kim D. Janda and Ian A. Wilson، نويسنده ,
Abstract :
Current treatments for cocaine addiction are not effective. The development of a catalytic monoclonal antibody (mAb) provides a strategy for not only binding, but also degrading cocaine, which offers a broad-based therapy. Hapten design is the central element for programming antibody catalysis. The characteristics of the linker used in classic transition-state analogue phosphonate haptens were shown to be important for obtaining mAbs that hydrolyze the benzoate ester of cocaine.